Wit (2001) and Stage IV Ovarian Cancer

Vivian Bearing is a formidable professor of seventeenth-century poetry. She is diagnosed with stage IV ovarian cancer and agrees to an experimental full-dose chemotherapy regimen. Over eight cycles she is reduced from a person to a research subject. The intellectual rigor that defined her turns out to be no defense at all.

Spoilers throughout. This page says how Wit ends.

Wit is used in medical and nursing education, and it earns that. The ward round conducted over her body. The researcher visibly more interested in the data than the patient. The moment an ordinary kindness from a nurse lands harder than any treatment.

Its handling of a do-not-resuscitate order is unusually unflinching, including what happens when that order is not honored in the moment. That is the scene most clinicians remember.

The film is also precise about a smaller thing: consent given by an exhausted person to a study she does not fully grasp. Vivian says yes because saying yes is what she has always done well. Nothing in the room slows down for her.

The film gives no statistics. SEER does. Ovarian cancer is projected by the American Cancer Society, on figures SEER carries, at 21,010 new cases and 12,450 deaths in the United States in 2026.

Stage at diagnosis is where the story is, for people diagnosed from 2016 through 2022:

• Localized: 22% of cases, 5-year relative survival 91.9%.
• Regional: 18% of cases, 70.1%.
• Distant: 54% of cases, 31.5%.
• Unstaged: 6% of cases, 38.5%.

More than half of ovarian cancers are already distant when found. Vivian is not an outlier. She is the modal case.

NCI states that ovarian epithelial, fallopian tube and peritoneal cancer may not cause early signs, and that when signs do appear the cancer is often advanced. Its list:

• Pain, swelling or a feeling of pressure in the abdomen or pelvis.
• A sudden or frequent urge to urinate.
• Trouble eating, or feeling full.
• A lump in the pelvic area.
• Gastrointestinal problems such as gas, bloating or constipation.

Every one of those is also a description of an ordinary week. NCI's own advice is about persistence: if they worsen or do not go away on their own, get them checked.

This is the point where the film's fatalism is medically correct. NCI's summary names three candidate screening tests. Gynecologic assessment. Vaginal ultrasonography. The CA-125 assay. All three, it says, have had low predictive value in women without special risk factors. The consequence shows up in stark arithmetic: annual mortality in ovarian cancer runs at roughly 65% of the incidence rate.

So there is no equivalent of a mammogram or a colonoscopy here. For the cancers where screening before symptoms genuinely works, see cancer screening. For the general point that one symptom is not an answer, see a symptom is not a diagnosis.

CA-125 appears in almost every ovarian cancer story, usually as a verdict. NCI treats it more carefully. It is a substance released by cells into the bloodstream. A raised level can be a sign of cancer, or of another condition such as endometriosis.

The PDQ adds two limits. CA-125 can be raised by other cancers, and by benign gynecologic problems. And its specificity and sensitivity are both low. Serial monitoring during treatment for recurrence may be useful. Whether it produces a net benefit has not been determined.

Vivian's regimen is an experiment, and the film is set before much of what follows existed.

NCI describes the usual approach to advanced ovarian cancer as surgery followed by platinum-based chemotherapy. Surgery aims to remove as much visible tumor as it safely can. That is called cytoreductive, or debulking, surgery.

Maintenance treatment came later. SOLO-1 tested it. The trial enrolled 391 people with newly diagnosed advanced disease and a BRCA1 or BRCA2 variant. After platinum chemotherapy they received olaparib tablets twice daily, at the trial's standard strength, or placebo. Anyone taking olaparib now should go by their own prescription, since the amount is often reduced. At a median 41 months, the risk of progression or death was 70% lower with olaparib. Progression-free survival at 3 years was 60%, against 27%.

These drugs carry their own risks. The FDA label for olaparib records myelodysplastic syndrome or acute myeloid leukemia in about 1.2% of treated patients, with most of those cases fatal. It directs that blood counts be checked at the start and monthly afterward.

That is the trade the film could not show, because in 2001 it did not exist yet.

Very little here is dramatized in the usual sense. The regimen is deliberately extreme because the argument requires it. If anything the film understates how much compassionate oncology care exists. It is a portrait of one research setting failing a person, not a survey of the field.

Nothing on this page is sponsored, and nothing here is for sale. Reader support is the reason it stays free. Support our work.

Wit is about what happens when a person is treated as a protocol. The medicine underneath is sound, and bleaker than most films dare. No screening test works at average risk. Most cases are found after spread. And the symptoms that come first look exactly like nothing.

• NCI — Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®), Health Professional Version
• NCI — Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®), Patient Version
• SEER Cancer Stat Facts: Ovarian Cancer
• openFDA drug label API — olaparib (LYNPARZA), Warnings and Precautions

This page discusses Wit for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care. Spotted an error? Please email [email protected].